Clenoliximab (INN[1]) is a monoclonal antibody against CD4. It acts as an immunomodulator and has been investigated for the treatment of rheumatoid arthritis.[2] The drug is a chimeric antibody from Macaca irus and Homo sapiens.[1]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Chimeric (primate/human) |
Target | CD4 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
DrugBank | |
ChemSpider |
|
UNII | |
![]() ![]() |
References
edit- ^ a b World Health Organization (1997). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 77" (PDF). WHO Drug Information. 11 (2): 89. Archived from the original (PDF) on June 27, 2004.
- ^ Hepburn TW, Totoritis MC, Davis CB (January 2003). "Antibody-mediated stripping of CD4 from lymphocyte cell surface in patients with rheumatoid arthritis". Rheumatology. 42 (1): 54–61. doi:10.1093/rheumatology/keg030. PMID 12509613.